3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Interventions
Bevacizumab
112
Fluorouracil
98
Oxaliplatin
96
Leucovorin
96
Irinotecan
86
Capecitabine
73
Cetuximab
64
Panitumumab
42
pembrolizumab
38
regorafenib
28
Nivolumab
23
IFL protocol
22
Folfox protocol
21
trifluridine tipiracil drug combination
14
Radiotherapy
13
durvalumab
11
Gemcitabine
10
Celecoxib
10
tremelimumab
7
binimetinib
7
aflibercept
7
Drug Therapy
7
Disulfides
7
Cyclophosphamide
7
Trifluridine
6
Trastuzumab
6
Sunitinib
6
Paclitaxel
6
Immunoglobulin G
6
Colonoscopy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Colorectal Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts